Beating the decision deadline by two days, the FDA cleared for marketing Santarus Inc.'s oral formulation of the corticosteroid budesonide, branded Uceris, for mild to moderate ulcerative colitis. Read More
Versartis Inc., of Redwood City, Calif., closed a $25 million Series C financing round through Aisling Capital, Index Ventures, New Leaf Venture Partners and Advent Venture Partners to support clinical trials of VRS-317 for growth hormone deficiency in children. Read More
LEBANON, N.H. – Despite its roots in small town USA, Adimab LLC is becoming the belle of the global biopharmaceutical ball, with a dance card that includes partners from all over the world. Read More
Globally, up to 520 million people may suffer from food allergies, according to the World Allergy Organization, and the prevalence in the industrialized world has been rising for 50 years. Read More
Although Galapagos NV is best known for its whopper of an alliance with AbbVie Inc. for its JAK inhibitor, GLPG0634, the company's rapidly growing drug discovery services business is set to expand further in 2013, following the acquisition of Cangenix Ltd., a UK-based specialist in structure-based discovery, and the establishment of its Fidelta unit in Croatia as an externally focused services arm. Read More
• Opexa Therapeutics Inc., of The Woodlands, Texas, said it was notified by Nasdaq that it has regained full compliance with the minimum bid price continued listing requirement. Read More
• Navidea Biopharmaceuticals Inc., of Dublin, Ohio, said it completed a study testing radiopharmaceutical NAV4694 as a biomarker for visual detection and quantification of cerebral beta-amyloid in diagnosing Alzheimer's disease. Read More
• Eli Lilly and Co., of Indianapolis, and subsidiary Avid Radiopharmaceuticals Inc. said Amyvid (florbetapir F 18 injection) was approved in Europe as a diagnostic radiopharmaceutical indicated for positron emission tomography imaging of beta-amyloid neuritic plaque density in the brains of adults with cognitive impairment who are being evaluated for Alzheimer's disease and other causes of cognitive impairment. Read More
